Next Phase Newsletter

A large pharmaceutical company headquartered in the US seeks to in-license assets and form partnerships with early-stage companies. For those fields, the firm is interested in first-in-class technology approaches and will invest in early companies with great science, from seed to series A. With their expansion to the US, the firm is now open to investing globally. The firm has generally led investments, but is willing to be part of a syndicate as well. The firm’s investments range based on the stage of the company, but will generally be no more than $5M for seed stage and no more than $10M for series A rounds.

Within therapeutics, the firm is open to both subsector and indication as long as the science is breakthrough. The firm is willing to invest earlier in platform technology companies, and will consider such technologies as early as POC stage. For companies with single assets in development, the firm prefers to see at least small animal data. For molecular diagnostics and digital health companies, the firm is opportunistic as well.

Because the firm invests early in companies with breakthrough science, they are willing to help their portfolio companies develop their strategies and operations. With its broad and trustful network with pharma companies, The firm helps portfolio companies’ boost their businesses development activities. The firm will take a board seat after investment if needed to help the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The fund is the venture capital arm of a US-based company, a global supplier of building materials as well as a manufacturer of innovative material solutions. The firm is looking for companies that will align with the company strategy for either equity investments, partnerships, licensing or acquisition. Within the life sciences, the firm will consider medical devices, novel materials, diagnostics, instruments and tools. The firm is willing to invest globally, and will invest as early as prototype/proof-of-concept stage.

Within the life sciences, the firm is interested in medical device, diagnostic or instrument and tool companies. The firm will consider all medical devices, but, if FDA approval is required, the fund prefers the company to be in the approval process. For diagnostics, the fund will consider both diagnostic/monitoring machines, tools, instruments & novel materials for Genomics & Cell & Gene therapies. The firm is also interested in instruments or tools that can be used in the medical field or for research purposes.

The firm can lead or co-invest in equity investing, and their involvement in the company after investment will depend on the partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A large pharmaceutical company headquartered in the US seeks to in-license assets and form partnerships with early-stage companies. The company’s investments and partnerships are varied in size, stage and structure. In addition to capital, early-stage partners may benefit from access to the company’s expertise and research capabilities. The firm will consider opportunities worldwide.

The company invests & partners diversely in therapeutic assets, including in Oncology, Neuroscience, Diabetes and Diabetes-Related Complications, Immunology, and Drug Delivery and Devices, in addition to discovery and research tools. Generally the firm has less interest in infectious diseases, ophthalmology, and rare diseases. The company focuses on assets that represent new biological modalities. The firm will also consider device investments on occasion. The firm will consider partnerships at any stage.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded in 2013 and based in MA, a medical technology venture firm makes equity investments in early-stage companies developing diagnostic technologies to accelerate the trend of precision medicine. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $5-15 M and is calibrated to milestone attainment. With a global view and global operational capabilities, the firm is currently seeking opportunities around the world.

The firm focuses on three market segments that support knowledge-generating precision medicine diagnosis: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) diagnostic technologies that guide or are a companion to precision therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.

The firm is looking for experienced management teams with deep domain expertise. The firm typically requests board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A private investment firm founded in 1965 and based in California invests in seed and early-stage digital health and therapeutic companies. Typical investment size for seed investment ranges from $500K to $1M (usually in equity or capped, convertible notes).  The firm typically co-invests with other VC firms in Seed and Series A financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based in the United States. The firm is actively seeking new investment opportunities.

The firm is actively seeking new investment opportunities in the digital health sector and areas of interest include: Precision medicine, digital therapeutics, combination data products, scalability solutions and clinical trial management solutions.

The firm often leads financings and takes a board seat, but prefers to syndicate on opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A New York City-based venture capital firm founded in 1999 has assets under management of about $135m and is investing from its third fund of outside capital, which closed in 2012. The firm invests in technology-enhanced services, and about 80% of the firm’s investments are in digital health technologies. Investments are in the form of equity or (less frequently) convertible debt, and the firm typically invests $500,000-$1.5 M. The firm invests in about 3-4 companies per year, and investments are typically made in Series A rounds. The firm primarily invests in the Northeast and Mid-Atlantic, but will consider investments outside those regions.

The firm invests broadly in the healthcare IT and analytics space, with past investments including a diagnostic platform, consumer wellness apps and health-focused media. They look for companies that provide software and data services to providers, payors, biopharmaceutical firms, and patients. The firm will consider investments related to any indication, but does not consider medical devices or therapeutic drugs. Activate Venture Partners invest only in companies that have fully developed a product.

The firm prefers to invest in companies that have existing revenues, but may consider pre-revenue companies with other strong evidence of their product’s market momentum such as adoption by free users. They like to see recurring revenue, high gross margins, and well-understood customer economics. The firm invests only in privately held companies but has no other set requirements for management.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

An early stage investor in emerging life science technologies has multiple offices in the USA. The firm seeks to invest in promising early-stage assets, create a company around each asset and then directly manage the startup. The firm’s investment sizes vary from $1-40 million. Investments are made at the seed stage or in Series A venture rounds; the firm prefers to be the first institutional investor. The firm has invested in assets sourced throughout the USA and has evaluated investment opportunities globally.

The firm primarily invests in therapeutics-focused opportunities. The firm is technologically agnostic and is open to any indication area, with a particular interest in CNS, digital health, oncology and immunology. The firm is interested in preclinical-stage assets and will consider investing in assets as early as the discovery stage.

The firm is open to working with both academic projects and entrepreneurs, and also deprioritized pharma assets. The firm generally does not make new investments into companies any later than the Series A stage. The firm supplies management and technical expertise to develop an asset if the company does not have a full management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.